CalciMedica (CALC) vs Moleculin Biotech (MBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Moleculin Biotech is the larger company by market cap ($9.0 million vs $8.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CALC | MBRX |
|---|---|---|
| Share price | $1.30 | $0.44 |
| Market cap | $8.88M | $8.97M |
| 1-day change | +0.01% | +3.78% |
| YTD return | -96.05% | — |
| 1-year return | -91.84% | — |
| P/E ratio (TTM) | — | 0.05 |
| EPS (TTM) | $-6.85 | $8.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.00 | $15.75 |
| 52-week low | $1.29 | $0.161 |
| Distance from 52-week high | -96.39% | -97.21% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +3745.86% | +2627.27% |
| Average volume | 75.54K | 1.29M |
| Shares outstanding | 6.83M | 20.39M |
| Employees | 15 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CalciMedica
CALC stock →CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Moleculin Biotech
MBRX stock →Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
CALC vs MBRX FAQ
Which is bigger, CalciMedica or Moleculin Biotech?
Moleculin Biotech (MBRX) is larger, with a market capitalization of $8.97M compared with $8.88M for CalciMedica (CALC).
Are CalciMedica and Moleculin Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.